First Cited
Last Cited

Articles citing This Document (Page 1 of 15)

Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial2022
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience
Factors influencing survival in metastatic castration resistant prostate cancer therapy
Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
Immediate Versus Salvage Postoperative Radiotherapy in High-Risk Prostate Cancer Patients: A Critical Review2022
Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer2022
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer2022
Systemic Treatments and Related Side Effects in Prostate Cancer2022
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancerScientific Reports2022
The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group)Medicina (Lithuania)2022
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborativeUrologic Oncology: Seminars and Original Investigations2022
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancerProstate Cancer and Prostatic Diseases
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trialActa Oncológica
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and TrendsClinical Drug Investigation
Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate CancerCancers2022
Prostate specif c antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapySiberian Journal of Oncology2022
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancerProstate
More Unacceptable Denials: Now It’s PSMA-Targeted PET/CT ImagingJournal of Nuclear Medicine2022
PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary MalignanciesCancers2022
The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort StudyJournal of Clinical Medicine2022
Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal RadiationInternational Journal of Particle Therapy2022
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked datasetUrologic Oncology: Seminars and Original Investigations2022
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case reportBMC Medical Genomics2022
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10Cancers2022
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and managementEuropean Journal of Nuclear Medicine and Molecular Imaging
Clinical implications of homologous recombination repair mutations in prostate cancerProstate2022
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapyBrachytherapy2022
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer Expert Review of Anticancer Therapy
Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017Cancer Medicine
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.Current Oncology Reports2022
Recent results of HDR brachytherapy in the treatment of localized forms of prostate cancerUkrainian Journal of Radiology and Oncology2022
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular Diagnosis and Therapy2022
Evolving trends in the management of low-risk prostate cancerClinical Genitourinary Cancer2022
Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study.Frontiers in Medicine2022
Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study.Radiation Oncology2022
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.BMC Cancer2022
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancerOnkologiya Zhurnal Imeni P A Gertsena2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.Journal of Medical Economics2022
"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI).International Journal of Radiation Oncology Biology Physics2022
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomyProstate2021
Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study.Prostate Cancer and Prostatic Diseases2021
Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal BalloonsInternational Journal of Particle Therapy2022
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.Research and Reports in Urology2022
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate AdenocarcinomaAdvances in Radiation Oncology2022